International Rhinologic Society Rhinology 0300-0729 2026 09 06 Real-world dupilumab treatment reduced healthcare resource utilization and medication use in patients with CRSwNP EN J.K. Han Department of Otolaryngology and Head and Neck Surgery, Old Dominion University, Norfolk, VA, United States S.E Lee Division of Otolaryngology—Head and Neck Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States A.T. Peters Division of Allergy and Immunology and the Sinus and Allergy Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States Z. Soler Department of Otolaryngology—Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, United States N. Kamal Global Medical Affairs, Sanofi, Dubai, United Arab Emirates S. Nash Medical Affairs, Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States M. Corbett Global Medical Affairs, Sanofi, Morristown, NJ, United States A. Radwan Regeneron Pharmaceuticals Inc., Uxbridge, United Kingdom J. Levy Department of Otolaryngology—Head and Neck Surgery, Emory University School of Medicine, Atlanta, GA, United States Journal Article 3509 10.4193/Rhin25.714 BACKGROUND: Evidence of dupilumab’s real-world effectiveness in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in US clinical practice is limited. OBJECTIVE: To investigate healthcare resource utilization (HCRU) and medication use in patients with CRSwNP before and after dupilumab initiation in real-world US clinical practice. METHODS: This retrospective observational study included adults with CRSwNP who initiated dupilumab 300 mg every 2 weeks between June 2019 and June 2022. Data including claims and electronic health records were extracted from the OM1 Real-World Data Cloud and Reg-ENT Registry. Medication use, healthcare visits, sinus procedures, and imaging were assessed during the 12 months before (baseline) and after (follow-up) dupilumab initiation. RESULTS: The study comprised 1,016 patients (mean age 53.8 years, 46.1% female). Annual mean [standard deviation] number of visits per patient was lower during follow-up vs baseline for outpatient (5.0 [5.2] vs 7.1 [6.0]), otolaryngologist (3.7 [6.7] vs 4.0 [6.1]) and emergency department visits (0.1 [0.6] vs 0.2 [0.6]). The proportion of patients prescribed oral corticosteroids for any reason was lower during follow-up (28.7% vs 68.1%, respectively. Fewer patients were prescribed antibiotics (31.8% vs 64.6%) and CRSwNP related oral corticosteroids (17.7% vs 59.1%), and fewer patients underwent nasal endoscopy (47.5% vs 71.2%) and CT scan (4.5% vs 22.1%) during follow-up than at baseline. CONCLUSIONS: These findings suggest an association between dupilumab treatment and reductions in HCRU and medication use in patients with CRSwNP, and provide supportive evidence of dupilumab’s real-world effectiveness.